Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL552961 | 0.87 | TAAR1 (0.66) | TAAR1CYP1A2CYP2D6CYP2C19GPR84 | |
| SCHEMBL1513555 | 0.82 | TAAR1 (0.63) | TAAR1CYP1A2CYP2D6CYP2C19SIGMAR1 | |
| SCHEMBL29979925 | 0.82 | TAAR1 (0.63) | TAAR1CYP1A2CYP2D6CYP2C19SIGMAR1 | |
| SCHEMBL2909601 | 0.81 | TAAR1 (1.00) | TAAR1CYP1A2CYP2D6CYP2C19GPR84 | |
| SCHEMBL8583518 | 0.81 | CYP1A2 (0.65) | TAAR1CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL29672948 | 0.81 | CYP1A2 (0.65) | TAAR1CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL552305 | 0.81 | TAAR1 (0.62) | TAAR1CYP1A2CYP2D6CYP2C19GPR84 | |
| Ammonia Solution, Strong SCHEMBL1766782 | 0.80 | TAAR1 (0.61) | TAAR1CYP1A2CYP2D6CYP2C19SIGMAR1 | |
| SCHEMBL21089609 | 0.80 | TAAR1 (0.60) | TAAR1CYP1A2CYP2D6CYP2C19GPR84 | |
| Hydrochloric Acid SCHEMBL7980053 | 0.79 | TAAR1 (0.96) | TAAR1CYP1A2CYP2D6CYP2C19GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354406-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | TAAR1 2652/4885CYP1A2 213/4885CYP2D6 1809/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | TAAR1 2652/4885CYP1A2 213/4885CYP2D6 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.